NORTH ASIA SCIENTIFIC ADVISORY BOARD NEWS
ARCHIMED is pleased to announce the launch of its North Asia Scientific Advisory Board, bringing together leading scientists to support its investment activities in Japan.
On April 13, the inaugural meeting of ARCHIMED’s North Asia Scientific Advisory Board (SAB) took place in Tokyo, marking an important milestone in ARCHIMED’s development in Japan. The event brought together four scientific advisors and seven ARCHIMED members, including senior investment and operational professionals, for the first time, discussing medical innovation and the future of healthcare technologies.
The SAB’s mission is to gather independent scientific expertise to help ARCHIMED assess the value of technologies and innovations in the context of its investment activities, ensuring that projects under review are both scientifically relevant and impactful. Each member is closely associated with the ARCHIMED team, united by a shared passion for medical innovation and its real-world impact on patients, healthcare practitioners, and society.
With expertise anchored in pharma and extending across ARCHIMED’s focused sectors, they bring insight in cutting-edge topics spanning systems biology and AI-driven drug discovery, genomic medicine and rare disease genetics, single-cell genomics and microfluidics, pharmaceutical R&D strategy and operations, and beyond.
Looking ahead, ARCHIMED will collaborate with the SAB through regular dialogue on innovation, portfolio developments, and emerging opportunities for impactful investment.
About the North Asia Scientific Advisory Board
The ARCHIMED North Asia Scientific Advisory Board is a multidisciplinary group of scientists closely associated with the ARCHIMED team, all driven by a shared interest in medical innovation and its impact on patients. Through independent scientific perspectives, rigorous evaluation of innovative technologies, and the identification of relevant opportunities, the board helps guide investments towards innovations that genuinely address medical needs and deliver real value to patients.
North Asia Scientific Advisory Board Members
Hiroaki Kitano
- Professor (adjunct), Okinawa Institute of Science and Technology Graduate University
- President, the Systems Biology Institute
Fumihiko Matsuda, Ph.D.
- Former Director & Professor, Center for Genomic Medicine at Kyoto University Graduate School of Medicine
Haruko Takeyama, Ph.D.
- Professor, Dept. of Life Science & Medical Bioscience, Waseda University School of Advanced Science & Engineering
Wataru Takasaki, Ph.D.
- Former R&D Head in Japan, Daiichi Sankyo Co., Ltd.